Progress on therapy for chronic obstructive pulmonary disease

Oral Presentation
Chairs: M. Cazzola (Naples, Italy), R. Dahl (Aarhus, Denmark)

Introduction: Evaluation criteria in clinical trials involving patients suffering from COPD M. Cazzola (Naples, Italy)
Relation between the acute response to salbutamol and long-term FEV1 responses to tiotropium (TIO), formoterol (FORM) and its combination (T+F) in COPD patients J. van Noord, J. Aumann, E. Janssens, A. Mueller, P. Cornelissen (Heerlen, The Netherlands; Hasselt, ; Lanaken, Belgium)
Glucocorticoid receptor alpha expression is reduced in lung parenchyma from COPD compared to normals and smokers subjects G. Caramori, E. Jazrawi, K. Ito, P. Casolari, K. F. Chung, A. Ciaccia, P. J. Barnes, I. M. Adcock, A. Papi (Ferrara, Italy; London, United Kingdom)
Once-daily mometasone furoate dry powder inhaler preserves lung function, reduces symptoms, and delays exacerbations in patients with COPD previously maintained on ICS P. M. A. Calverley, R. Pauwels, M. Nieminem, P. Stryszak, H. Staudinger, T. Lee (Liverpool, United Kingdom; Ghent, Belgium; Tampere, Finland; Kenilworth, United States Of America)
Comparison of the acute effects of formoterol (F) and formoterol/budesonide combination (FBC) on blood-gas tensions in patients with acute exacerbation of COPD (AECOPD) P. Noschese, F. De Michele, G. D‘Amato, M. Cazzola (Naples, Italy)
Histone deacetylase activity is reduced in COPD. Modulation by theophylline B. G. Cosio, K. Ito, E. Jazrawi, P. Shah, O. M. Kon, F. Chung, I. M. Adcock, P. J. Barnes (London, United Kingdom)
Effects of treatment with N-acetylcysteine or inhaled corticosteroids on inflammatory mediators in COPD-patients F. J. van Overveld, U. A. Demkow, D. Gorecka, P. Bielen, B. Bialas-Chromiec, A. Zdral, A. Sadowska, M. Filewska, J. Zielinski, W. A. De Backer (Antwerp, Belgium; Warsaw, Poland)
Effect of recombinant α-1 antitrypsin (rAAT) and TAPI on neutrophil elastase (NE) and matrix metalloproteinase-9 (MMP9) activity in induced sputum (IS) from healthy smokers and patients with chronic obstructive pulmonary disease (COPD) J. R. Topping, E. J. Vanden Bon, R. C. Tennant, T. T. Hansel, P. J. Barnes, P. J. Barr, P. A. Pemberton, D. J. Sundin, T. D. Tetley (London, United Kingdom; Alameda)